Radiotherapy 23 x 1.8 Gy

RADIATION2 trials

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Peking Union Medical College Hospital

Conditions

Esophageal Cancer Stage IIIEsophageal Cancer, Stage IIEsophageal Squamous Cell Carcinoma

Phase 2

PDL-1 Targeting in Resectable Oesophageal Cancer

CompletedNCT03087864

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Esophageal Cancer, Stage II, Esophageal Cancer Stage III

Start: 2017-06-28End: 2019-07-01Updated: 2020-05-11

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

CompletedNCT04568200

Peking Union Medical College HospitalEsophageal Squamous Cell Carcinoma

Start: 2020-06-19End: 2024-01-01Updated: 2024-01-22

Related Papers

Neoadjuvant immunotherapy combined with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II trial.

Journal of Clinical Oncology2026-05-28

Neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

Journal of Clinical Oncology2025-05-28

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

OncoImmunology2023-07-177 citations

Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.

Journal of Clinical Oncology2021-05-20

Intestinal and tumor microbiome analysis combined with metabolomics of the anti-PD-L1 phase II PERFECT trial for resectable esophageal adenocarcinoma.

Journal of Clinical Oncology2020-05-201 citations

A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.

Journal of Clinical Oncology2019-05-2024 citations